Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

Alfie, who Duchenne Muscular Dystrophy, wants to walk on the pitch at a Liverpool FC game and watch a football match abroad.

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2025 and recent business highlights.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.